Meyer Handelman CO Regeneron Pharmaceuticals, Inc. Transaction History

Meyer Handelman CO

$2.83 Billion
Q2 2024

A detailed history of Meyer Handelman CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Meyer Handelman CO holds 4,265 shares of REGN stock, worth $4.44 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

4,265

Previous 4,265 -0.0%

Holding current value

$4.44 Million

Previous $4.11 Million 9.18%

% of portfolio

0.16%

Previous 0.14%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 17, 2024	BUY	$775.18 - $881.7 $23,255 - $26,451	30 Added 0.71%	4,265 $3.75 Million
Q3 2023 Nov 06, 2023	BUY	$692.45 - $844.37 $301,215 - $367,300	435 Added 11.45%	4,235 $3.49 Million
Q2 2023 Jul 21, 2023	BUY	$700.03 - $830.35 $157,506 - $186,828	225 Added 6.29%	3,800 $2.73 Million
Q1 2023 Apr 11, 2023	BUY	$680.49 - $826.97 $47,634 - $57,887	70 Added 2.0%	3,575 $2.94 Million
Q4 2022 Jan 25, 2023	BUY	$705.89 - $766.39 $2.47 Million - $2.69 Million	3,505 New	3,505 $2.53 Million
Q3 2022 Oct 04, 2022	BUY	$573.97 - $724.32 $28,698 - $36,216	50 Added 1.39%	3,655 $2.52 Million
Q1 2022 Apr 06, 2022	BUY	$595.12 - $698.43 $273,755 - $321,277	460 Added 14.63%	3,605 $2.52 Million
Q4 2021 Jan 25, 2022	BUY	$543.48 - $670.97 $95,109 - $117,419	175 Added 5.89%	3,145 $1.99 Million
Q2 2021 Aug 18, 2021	BUY	$472.8 - $558.54 $342,780 - $404,941	725 Added 32.29%	2,970 $1.66 Million
Q1 2021 May 03, 2021	BUY	$446.73 - $548.2 $1 Million - $1.23 Million	2,245 New	2,245 $1.06 Million

Others Institutions Holding REGN

# of Institutions

1,463

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meyer Handelman CO, based on Form 13F filings with the SEC.

News

Stay updated on Meyer Handelman CO with notifications on news.

Account

Meyer Handelman CO Regeneron Pharmaceuticals, Inc. Transaction History